Likelihood of aggressive PK/PD target attainment of continuous-infusion beta-lactams during the first week of treatment of febrile neutropenia: findings from a 1-year prospective, monocentric study in onco-haematological patients
Pier Giorgio Cojutti(Azienda USL di Bologna), Federico Pea(Azienda USL di Bologna), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Alice Toschi(Azienda USL di Bologna), Pierluigi Viale(Azienda USL di Bologna), Maddalena Giannella(Azienda USL di Bologna), Stefania Paolini(Azienda USL di Bologna), Francesca Bonifazi(Azienda USL di Bologna), Zeno Pasquini(Azienda USL di Bologna), Enrico Maffini(Istituto di Ematologia di Bologna)
Cited by 0
Related Papers
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
ALK+ lymphoma: clinico-pathological findings and outcome.
|PubMed|1999|569
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523